These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15196814)

  • 61. Polysulfated sialic acid derivatives as anti-human immunodeficiency virus.
    Terada M; Fujita S; Suda I; Mastico R
    Biomed Pharmacother; 2005 Sep; 59(8):423-9. PubMed ID: 16143490
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Macrophage-induced inflammation affects hippocampal plasticity and neuronal development in a murine model of HIV-1 encephalitis.
    Poluektova L; Meyer V; Walters L; Paez X; Gendelman HE
    Glia; 2005 Dec; 52(4):344-53. PubMed ID: 16078235
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A hepatitis C virus xenograft mouse efficacy model.
    Zhu Q; Weiner AJ
    Methods Mol Biol; 2009; 511():323-31. PubMed ID: 19347304
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The SCID-hu mouse: an in vivo model for HIV-1 infection in humans.
    Bonyhadi ML; Kaneshima H
    Mol Med Today; 1997 Jun; 3(6):246-53. PubMed ID: 9211415
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pyridine N-oxide derivatives: unusual anti-HIV compounds with multiple mechanisms of antiviral action.
    Balzarini J; Stevens M; De Clercq E; Schols D; Pannecouque C
    J Antimicrob Chemother; 2005 Feb; 55(2):135-8. PubMed ID: 15650002
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Use of hydroxyurea in heavily pretreated patients with HIV infection.
    Hermans P; De Wit S; Sommereijns B; O'Doherty E; Clumeck N
    Antivir Ther; 1999; 4 Suppl 3():19-22. PubMed ID: 16021867
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Silencing HIV-1 In Vivo.
    Kirchhoff F
    Cell; 2008 Aug; 134(4):566-8. PubMed ID: 18724929
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [The immunodeficient mouse (SCID) as an animal model for AIDS].
    Pasqualini CD
    Medicina (B Aires); 1990; 50(3):272-3. PubMed ID: 2130217
    [No Abstract]   [Full Text] [Related]  

  • 69. Potent activity of 2'-beta-fluoro-2',3'-dideoxyadenosine against human immunodeficiency virus type 1 infection in hu-PBL-SCID mice.
    Ruxrungtham K; Boone E; Ford H; Driscoll JS; Davey RT; Lane HC
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2369-74. PubMed ID: 8891146
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mathematical models of HIV and the immune system.
    Wodarz D
    Novartis Found Symp; 2003; 254():193-207; discussion 207-22, 250-2. PubMed ID: 14712939
    [TBL] [Abstract][Full Text] [Related]  

  • 71. U937-SCID mouse xenografts: a new model for acute in vivo HIV-1 infection suitable to test antiviral strategies.
    Lapenta C; Fais S; Rizza P; Spada M; Logozzi MA; Parlato S; Santini SM; Pirillo M; Belardelli F; Proietti E
    Antiviral Res; 1997 Nov; 36(2):81-90. PubMed ID: 9443664
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Simple i.v. inoculation of HIV-1 to Thy/Liv SCID-hu mice induce reproducible HIV infection with narrowing of medulla in human thymic implant.
    Okamoto Y; Ogura A; Shibata S; Amagai T; Katsura Y; Asano T; Honda M
    J Vet Med Sci; 1997 Apr; 59(4):259-63. PubMed ID: 9152933
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Novel mouse models for understanding HIV-1 pathogenesis.
    Joseph A; Sango K; Goldstein H
    Methods Mol Biol; 2009; 485():311-27. PubMed ID: 19020834
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry.
    Datema R; Rabin L; Hincenbergs M; Moreno MB; Warren S; Linquist V; Rosenwirth B; Seifert J; McCune JM
    Antimicrob Agents Chemother; 1996 Mar; 40(3):750-4. PubMed ID: 8851605
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Preclinical evaluation of antiviral compounds in the SCID-hu mouse.
    McCune JM; Kaneshima H; Rabin L; Shih CC; Namikawa R
    Ann N Y Acad Sci; 1990; 616():281-6. PubMed ID: 2078024
    [No Abstract]   [Full Text] [Related]  

  • 76. Today's SCID-hu mouse.
    Kaneshima H; Baum C; Chen B; Namikawa R; Outzen H; Rabin L; Tsukamoto A; McCune JM
    Nature; 1990 Dec; 348(6301):561-2. PubMed ID: 2247165
    [No Abstract]   [Full Text] [Related]  

  • 77. Evaluation of anti-AIDS drugs in conventional mice implanted with a permeable membrane device containing human T cells infected with HIV.
    Quenelle DC; Keith KA; Dunleavy KE; Taylor BA; Bowdon BJ; Brazier AD; Mullon CJ; HarrisRE ; Allen LB
    Antiviral Res; 1997 Jul; 35(2):123-9. PubMed ID: 9217249
    [TBL] [Abstract][Full Text] [Related]  

  • 78. In vivo drug screening applications of HIV-infected cells cultivated within hollow fibers in two physiologic compartments of mice.
    Hollingshead M; Roberson J; Decker W; Buckheit R; Elder C; Malspeis L; Mayo J; Grever M
    Antiviral Res; 1995 Nov; 28(3):265-79. PubMed ID: 8629818
    [TBL] [Abstract][Full Text] [Related]  

  • 79. TXU (anti-CD7)-pokeweed antiviral protein as a potent inhibitor of human immunodeficiency virus.
    Uckun FM; Chelstrom LM; Tuel-Ahlgren L; Dibirdik I; Irvin JD; Langlie MC; Myers DE
    Antimicrob Agents Chemother; 1998 Feb; 42(2):383-8. PubMed ID: 9527790
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Chimeric SCID-hu Model as a Human Hematopoietic Stem Cell Host That Recapitulates the Effects of HIV-1 on Bone Marrow Progenitors in Infected Patients.
    Sundell IB; Koka PS
    J Stem Cells; 2006; 1(4):283-300. PubMed ID: 19030112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.